PUBH5019 Chap.1 Cancer Biology, Causation and Genetic Risk
Cancer Biology, Causation and Genetic Risk
Cancer control includes actions that reduce exposure and susceptibility, detect disease earlier where screening is beneficial, improve diagnosis and treatment, support survivorship and provide palliative care. Population policy, health services, communities and individuals all contribute.
The continuum prevents primary prevention from being treated as the only legitimate control and prevents treatment improvement from erasing avoidable differences in incidence or access. Cancer develops through cellular changes that alter growth, survival, genome maintenance and interaction with surrounding tissue. Driver mutations contribute to selective advantage, whereas passenger mutations need not drive the process.
Proto-oncogenes can become overactive, tumour-suppressor functions can be lost and DNA-repair defects can increase the accumulation of change. The route varies across cancers and within a tumour over time. Smoking, radiation, infection and other exposures can raise cancer risk without producing disease in every exposed person, while cancers also occur among people without the focal exposure.
Multifactorial causation involves timing, dose, susceptibility, competing causes and chance. Public-health reasoning therefore uses population evidence to estimate change in probability and preventable burden, not to assign blame or predict an individual's outcome with certainty.
Some inherited variants are rare and can confer substantial risk within affected families, while polygenic risk scores aggregate many common variants with small estimated effects. The architectures support different evidence and communication. Neither removes environmental influence or uncertainty, and both require careful validation across populations.
A score ranks risk relative to a reference; it does not diagnose cancer or state an inevitable future. Genomic information can refine cancer classification, inherited-risk assessment or treatment selection, but its value depends on a chain: a reliable test, valid interpretation, meaningful risk or response estimate, available action and informed choice. Breaking any link reduces utility.
Population programmes must also consider infrastructure, workforce, privacy, family implications and whether tailoring diverts resources from broadly effective prevention.
What this chapter covers
- 01
Cancer control spans the whole pathway
- 02
Driver mutations disrupt growth control in different ways
- 03
Risk factors change probability, not certainty
- 04
Rare variants and polygenic scores describe different architectures
- 05
Genomic knowledge needs context before tailoring control
- 06
Control is broader than avoiding the first malignant cell
- 07
Cancer biology is an evolving process, not one switch
- 08
A causal exposure can remain neither necessary nor sufficient
- 09
Genetic risk depends on effect, frequency and context
- 10
Personalisation is a system of decisions, not a test result
Connect cancer control spans the whole pathway to a defensible decision
- 1Name the precise concept from cancer control spans the whole pathway that fits the observable evidence.
- 1Separate the description of the case from the inference being made about it.
- 1Use genomic knowledge needs context before tailoring control to compare at least one plausible alternative.
- 1State the evidence boundary and one finding that would change the recommendation.
Key terms
- Cancer control spans the whole pathway
- Join prevention, detection, treatment, survivorship and palliation without losing level.
- Driver mutations disrupt growth control in different ways
- Separate oncogenes, tumour suppressors, repair systems and clonal selection.
- Risk factors change probability, not certainty
- Keep association, causation and individual outcome analytically distinct.
Cancer Biology, Causation and Genetic Risk FAQ
Which population-health question is answered by cancer control spans the whole pathway?
Cancer control includes actions that reduce exposure and susceptibility, detect disease earlier where screening is beneficial, improve diagnosis and treatment, support survivorship and provide palliative care. Population policy, health services, communities and individuals all contribute.
The continuum prevents primary prevention from being treated as the only legitimate control and prevents treatment improvement from erasing avoidable differences in incidence or access.
What evidence boundary belongs around driver mutations disrupt growth control in different ways?
Cancer develops through cellular changes that alter growth, survival, genome maintenance and interaction with surrounding tissue. Driver mutations contribute to selective advantage, whereas passenger mutations need not drive the process. Proto-oncogenes can become overactive, tumour-suppressor functions can be lost and DNA-repair defects can increase the accumulation of change.
The route varies across cancers and within a tumour over time.
How can bias distort a claim about risk factors change probability, not certainty?
Smoking, radiation, infection and other exposures can raise cancer risk without producing disease in every exposed person, while cancers also occur among people without the focal exposure. Multifactorial causation involves timing, dose, susceptibility, competing causes and chance.
Public-health reasoning therefore uses population evidence to estimate change in probability and preventable burden, not to assign blame or predict an individual's outcome with certainty.
Which intervention lever follows from understanding rare variants and polygenic scores describe different architectures?
Some inherited variants are rare and can confer substantial risk within affected families, while polygenic risk scores aggregate many common variants with small estimated effects. The architectures support different evidence and communication. Neither removes environmental influence or uncertainty, and both require careful validation across populations.
A score ranks risk relative to a reference; it does not diagnose cancer or state an inevitable future.
What equity test should accompany genomic knowledge needs context before tailoring control?
Genomic information can refine cancer classification, inherited-risk assessment or treatment selection, but its value depends on a chain: a reliable test, valid interpretation, meaningful risk or response estimate, available action and informed choice. Breaking any link reduces utility.
Population programmes must also consider infrastructure, workforce, privacy, family implications and whether tailoring diverts resources from broadly effective prevention.
Assessment move
Build a chapter ledger around cancer control spans the whole pathway, driver mutations disrupt growth control in different ways, risk factors change probability, not certainty, rare variants and polygenic scores describe different architectures, genomic knowledge needs context before tailoring control. For each class example, record the observable fact before attaching a concept.
Add a second column for the mechanism that connects evidence to the claim, a third for a credible alternative explanation, and a fourth for the information still missing. Rehearse by converting one descriptive sentence into a bounded analytical claim, then try to falsify it with a counterexample. At the end of the week, choose one decision and explain it aloud without relying on a definition list.
The explanation should name the actor, setting, mechanism, consequence and evidence limit. Redraft any passage that jumps from a label directly to advice. Compare the redraft with the current task criteria and preserve a short source trail for figures, examples and factual assertions.
Before submission, reverse the process: underline every recommendation, trace it back to evidence, and ask whether a competing interpretation was genuinely considered. This routine makes the chapter useful for both short responses and extended applied work without turning the concepts into interchangeable slogans.
Working through Cancer Biology, Causation and Genetic Risk in PUBH5019? Sia is AskSia’s AI Public Health tutor — ask any PUBH5019 Cancer Biology, Causation and Genetic Risk question and get a clear, step-by-step explanation grounded in how PUBH5019 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
USyd PUBH5010 Epidemiology Methods and Uses · USyd AMED3001 Cancer · USyd HSBH1012 Introduction to Health and Health Care
